Phase II studies on docetaxel alone every third week, or weekly in combination with gemcitabine in patients with primary locally advanced, metastatic, or recurrent esophageal cancer.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples